Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-ESPRIT – Enhancing recovery in early schizophrenia
2024-517198-26-00Phase 2Suspended
- Sponsor
- Central Institute of Mental Health
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Cannabidiol add-on with Placebo add-on (2 arms). Primary endpoint: All-cause discontinuation within 12 months. Started Nov 2024; status: suspended.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-517198-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517198-26-00.